ES2652027T3 - Estratificación de riesgo del síndrome coronario agudo por medio de fragmentos / péptidos parciales de la provasopresina, en particular copeptina o neurofisina II - Google Patents

Estratificación de riesgo del síndrome coronario agudo por medio de fragmentos / péptidos parciales de la provasopresina, en particular copeptina o neurofisina II Download PDF

Info

Publication number
ES2652027T3
ES2652027T3 ES07846265.2T ES07846265T ES2652027T3 ES 2652027 T3 ES2652027 T3 ES 2652027T3 ES 07846265 T ES07846265 T ES 07846265T ES 2652027 T3 ES2652027 T3 ES 2652027T3
Authority
ES
Spain
Prior art keywords
diagnosis
acute coronary
copeptin
neurophysin
coronary syndrome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES07846265.2T
Other languages
English (en)
Spanish (es)
Inventor
Andreas Bergmann
Nils Morgenthaler
Jana Papassotiriou
Joachim Struck
L. Ng Leong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BRAHMS GmbH
Original Assignee
BRAHMS GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE200610050497 external-priority patent/DE102006050497A1/de
Priority claimed from DE200610057409 external-priority patent/DE102006057409A1/de
Application filed by BRAHMS GmbH filed Critical BRAHMS GmbH
Application granted granted Critical
Publication of ES2652027T3 publication Critical patent/ES2652027T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2410/00—Assays, e.g. immunoassays or enzyme assays, involving peptides of less than 20 animo acids
    • G01N2410/04—Oxytocins; Vasopressins; Related peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
ES07846265.2T 2006-10-26 2007-10-26 Estratificación de riesgo del síndrome coronario agudo por medio de fragmentos / péptidos parciales de la provasopresina, en particular copeptina o neurofisina II Active ES2652027T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE200610050497 DE102006050497A1 (de) 2006-10-26 2006-10-26 Risikostratifizierung des akuten Koronarsyndroms mittels Fragmenten / Teilpeptiden des proVasopressins, insbesondere Copeptin oder Neurophysin II
DE102006050497 2006-10-26
DE200610057409 DE102006057409A1 (de) 2006-12-04 2006-12-04 Risikostratifizierung des akuten Koronarsyndroms mittels Fragmenten / Teilpeptiden des proVasopressins, insbesondere Copeptin oder Neurophysin II
DE102006057409 2006-12-04
PCT/DE2007/001928 WO2008049422A2 (de) 2006-10-26 2007-10-26 Risikostratifizierung des akuten koronarsyndroms mittels fragmenten / teilpeptiden des provasopressins, insbesondere copeptin oder neurophysin ii

Publications (1)

Publication Number Publication Date
ES2652027T3 true ES2652027T3 (es) 2018-01-31

Family

ID=39276269

Family Applications (1)

Application Number Title Priority Date Filing Date
ES07846265.2T Active ES2652027T3 (es) 2006-10-26 2007-10-26 Estratificación de riesgo del síndrome coronario agudo por medio de fragmentos / péptidos parciales de la provasopresina, en particular copeptina o neurofisina II

Country Status (8)

Country Link
US (3) US8501485B2 (enExample)
EP (1) EP2084543B1 (enExample)
JP (2) JP5320294B2 (enExample)
DE (1) DE112007003185A5 (enExample)
DK (1) DK2084543T3 (enExample)
ES (1) ES2652027T3 (enExample)
PL (1) PL2084543T3 (enExample)
WO (1) WO2008049422A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140046407A1 (en) * 2001-08-31 2014-02-13 Bio Control Medical (B.C.M.) Ltd. Nerve stimulation techniques
EP1628136A1 (en) * 2004-08-19 2006-02-22 B.R.A.H.M.S. Aktiengesellschaft Method of diagnosis of disease using copeptin
WO2007121495A2 (en) * 2006-04-24 2007-11-01 Medizinische Universität Wien Method for diagnosing cardiovascular diseases
DE112007003185A5 (de) * 2006-10-26 2009-10-01 Brahms Aktiengesellschaft Risikostratifizierung des akuten Koronarsyndroms mittels Fragmenten / Teilpeptiden des proVasopressins, insbesondere Copeptin oder Neurophysin II
DE102006058266A1 (de) * 2006-12-08 2008-06-12 Brahms Aktiengesellschaft Diagnose und Risikostratifizierung von Herzinsuffizienz mittels Neurophysin
DE102007009751A1 (de) 2007-02-28 2008-09-04 B.R.A.H.M.S Aktiengesellschaft Verfahren zur selektiven Bestimmung von Procalcitonin 1-116 für diagnostische Zwecke sowie Antikörper und Kits zur Durchführung eines solchen Verfahrens
ES2724478T3 (es) 2008-10-24 2019-09-11 Brahms Gmbh Pronóstico y evaluación del riesgo en pacientes con accidente cerebrovascular determinando el nivel de péptidos marcadores
CN102317788A (zh) * 2008-10-31 2012-01-11 B.R.A.H.M.S有限公司 用作糖尿病预测生物标志物的精氨酸加压素激素原
DK2427764T3 (en) * 2009-05-05 2017-09-11 Brahms Gmbh VASOACTIVE HORMON-BASED STRATIFICATION OF PATIENTS SUFFERING OF DISEASES RELATED TO ENDOTELIAL FUNCTION / DYSFUNCTION
RU2618437C2 (ru) * 2010-11-01 2017-05-03 Б.Р.А.Х.М.С Гмбх Оценка прогноза и риска пациентов с неспецифическими жалобами
EP2533052A1 (en) * 2011-06-07 2012-12-12 B.R.A.H.M.S GmbH Diagnostic use of proSomatostatin
JP6403572B2 (ja) * 2011-09-08 2018-10-10 ネクサス・ディーエックス・インコーポレイテッドＮｅｘｕｓ Ｄｘ， Ｉｎｃ． マルチレベル分析物アッセイ
EP4574024A3 (en) 2016-02-01 2025-10-08 Prevencio, Inc. Diagnostic and prognostic methods for cardiovascular diseases and events
US11446009B2 (en) 2018-12-11 2022-09-20 Eko.Ai Pte. Ltd. Clinical workflow to diagnose heart disease based on cardiac biomarker measurements and AI recognition of 2D and doppler modality echocardiogram images
US12001939B2 (en) 2018-12-11 2024-06-04 Eko.Ai Pte. Ltd. Artificial intelligence (AI)-based guidance for an ultrasound device to improve capture of echo image views
US12322100B2 (en) 2018-12-11 2025-06-03 Eko.Ai Pte. Ltd. Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and grading of aortic stenosis severity
US11931207B2 (en) 2018-12-11 2024-03-19 Eko.Ai Pte. Ltd. Artificial intelligence (AI) recognition of echocardiogram images to enhance a mobile ultrasound device
US12400762B2 (en) 2018-12-11 2025-08-26 Eko.Ai Pte. Ltd. Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and diagnosis of cardiac amyloidosis and hypertrophic cardiomyopathy
KR102318236B1 (ko) * 2020-02-18 2021-10-26 한림대학교 산학협력단 혈중 코펩틴의 농도를 이용한 지연성 뇌허혈 진단 방법

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9305142D0 (en) * 1993-03-12 1993-04-28 Medinnova Sf Method
DE60233301D1 (de) 2001-05-04 2009-09-24 Biosite Inc Diagnostische marker für akute herzerkrankungen und verfahren des gebrauchs
MXPA03004105A (es) 2002-05-14 2004-10-15 Hoffmann La Roche Elaboracion de una prognosis en casos de enfermedad cardiaca usando una combinacion de marcadores.
WO2004006860A2 (en) 2002-07-16 2004-01-22 Woomera Therapeutics, Inc. Compositions and uses thereof for identifying and targeting provasopressin-expressing cancer cells
CA2485722A1 (en) * 2003-10-22 2005-04-22 Paul Lehmann Soluble transferrin receptor
EP1530047A1 (en) * 2003-11-07 2005-05-11 Roche Diagnostics GmbH Proximal markers of arterial thrombosis and inflammation for risk stratification of coronary heart disease
EP1628136A1 (en) * 2004-08-19 2006-02-22 B.R.A.H.M.S. Aktiengesellschaft Method of diagnosis of disease using copeptin
DE102004051847B4 (de) * 2004-10-25 2008-09-18 Dade Behring Marburg Gmbh Verhältnis von PIGF und Flt-1 als prognostischer Parameter bei kardio-vaskulären Erkrankungen
EP2924440A3 (en) * 2006-06-07 2016-03-09 Health Diagnostic Laboratory, Inc. Markers associated with arteriovascular events and methods of use thereof
DE112007003185A5 (de) * 2006-10-26 2009-10-01 Brahms Aktiengesellschaft Risikostratifizierung des akuten Koronarsyndroms mittels Fragmenten / Teilpeptiden des proVasopressins, insbesondere Copeptin oder Neurophysin II
DE102006053442A1 (de) * 2006-11-12 2008-05-15 Brahms Aktiengesellschaft Diagnose und Risikostratifizierung von Infektionen und chronischen Erkrankungen der Atemwege und Lunge mittels proVasopressin, insbesondere Copeptin oder Neurophysin II
DE102006058266A1 (de) * 2006-12-08 2008-06-12 Brahms Aktiengesellschaft Diagnose und Risikostratifizierung von Herzinsuffizienz mittels Neurophysin
DE102007021443A1 (de) * 2007-05-08 2008-11-13 Brahms Aktiengesellschaft Diagnose und Risikostratifizierung mittels NT-proET-1
EP2148203A1 (en) * 2008-07-23 2010-01-27 BRAHMS Aktiengesellschaft Azurophilic granule proteases as markers in cardiological diseases
ES2724478T3 (es) * 2008-10-24 2019-09-11 Brahms Gmbh Pronóstico y evaluación del riesgo en pacientes con accidente cerebrovascular determinando el nivel de péptidos marcadores

Also Published As

Publication number Publication date
US8501485B2 (en) 2013-08-06
US9261517B2 (en) 2016-02-16
EP2084543B1 (de) 2017-10-18
DE112007003185A5 (de) 2009-10-01
US10254289B2 (en) 2019-04-09
WO2008049422A2 (de) 2008-05-02
US20130344513A1 (en) 2013-12-26
JP5320294B2 (ja) 2013-10-23
PL2084543T3 (pl) 2018-04-30
DK2084543T3 (en) 2018-01-22
US20160131660A1 (en) 2016-05-12
JP2013178249A (ja) 2013-09-09
WO2008049422A3 (de) 2009-01-15
JP2010507786A (ja) 2010-03-11
EP2084543A2 (de) 2009-08-05
US20100028921A1 (en) 2010-02-04
HK1137808A1 (en) 2010-08-06

Similar Documents

Publication Publication Date Title
ES2652027T3 (es) Estratificación de riesgo del síndrome coronario agudo por medio de fragmentos / péptidos parciales de la provasopresina, en particular copeptina o neurofisina II
ES2430218T3 (es) Diagnóstico y estratificación de riesgo mediante NT-proET-1
EP1889073B1 (en) Use of nt-proanp and nt-probnp for diagnosing cardiac diseases
JP5190067B2 (ja) Ｎｔ−プロｂｎｐと組み合わせてのｃｔ−プロｅｔ−１による急性冠症候群の診断および危険性の分類
EP1859283A1 (en) Use of nt-proanp/nt-probnp ratio for diagnosing cardiac dysfunctions
ES2293356T3 (es) Diagnostico de enfermedades isquemicas agudas de miocardio por combinacion de marcadores.
Giannopoulos et al. Copeptin as a biomarker in cardiac disease
JP2013210385A (ja) ニューロフィジンを使用する心機能不全の診断および危険性の層化
Casey Markers of myocardial injury and dysfunction
CN101600967B (zh) 和肽素或后叶激素运载蛋白ii在制备急性冠状动脉综合征危险性分级试剂盒的用途
Omland et al. N-terminal pro-B-type natriuretic peptide
HK1135185B (en) Kit for diagnosis and risk stratification of cardiac insufficiency using neurophysin
HK1137808B (en) Use of copertin or neurophysin ii in the manufacture of a kit for risk stratification for acute coronary syndrome
HK1140547B (en) Diagnosis and risk classification of acute coronary syndrome by means of ct-proet-1 in combination with nt-probnp
WO2006117410A1 (es) Uso de un fragmento c-terminal de cardiotrofina-1 como marcador de cardiotrofina-1